Consensus Statement on the Role of Dermoceuticals in the Management of Atopic Dermatitis in the United Arab Emirates

Authors: Al Naeem, Ayman; Ameen, Ahmed; Al Awadhi, Ameen; Reda, Ashraf M; Attia, Enas; Albreiki, Fatima; Almarzooqi, Fatima; Rajab Ali, Huda; Abdel Dayem, Hussein; Aljefri, Khadija; Al Murrawi, Muna; Al Maashari, Raghda; Goturu, Srikumar; Steinhoff, Martin

Source journal: Dermatology and therapy (2026-11-20)

DOI: 10.1007/s13555-026-01983-9

Abstract

INTRODUCTION: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease characterized by epidermal barrier dysfunction, immune dysregulation, microbiome alterations, and persistent pruritus. Dermoceuticals have become an integral component of AD management because of their role in restoring skin barrier function, maintaining hydration, reducing symptoms, and complementing pharmacological therapies. However, practical guidance on their optimal selection and integration into routine clinical practice remains limited within the United Arab Emirates (UAE). This consensus manuscript aimed to develop evidence-informed statements on the use of dermoceuticals in the management of AD in the UAE. METHODS: A panel of 13 experienced dermatologists representing public and private healthcare sectors across the UAE, together with an international expert serving as an external scientific validator, developed the statements through a structured modified Delphi process informed by a targeted literature review. Consensus was defined as >/= 80% agreement. RESULTS: Following two rounds of anonymous voting, consensus was achieved for 13 of the 14 proposed statements. One statement concerning treatment selection in active and mild AD did not achieve consensus and was excluded. The 13 final statements addressed AD pathophysiology, treatment goals, the definition and role of dermoceuticals, moisturizer formulations, microbiome-supportive skincare, gentle cleansers, ceramide-containing formulations, proactive maintenance therapy, shared decision-making, and patient and caregiver education. The panel emphasized that dermoceuticals should be considered a lifelong component of individualized AD management, serving as monotherapy in selected patients with mild disease and as adjunctive therapy alongside pharmacological treatment in moderate-to-severe AD. CONCLUSIONS: These consensus recommendations provide practical guidance for integrating dermoceuticals into routine clinical practice in the UAE and aim to support standardized, evidence-informed, patient-centered care while optimizing long-term disease control and quality of life.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.